All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV showed no clear difference in mortality compared with HAART alone (moderate certainty).
1 finding from 1 review
All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
Oral etoposide showed no clear difference in mortality compared with ABV (moderate certainty).
1 finding from 1 review
All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
It is very uncertain whether bleomycin changes mortality compared with ABV (very low certainty).
1 finding from 1 review
All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
Liposomal doxorubicin showed no clear difference in mortality compared with conservative management (moderate certainty).
1 finding from 1 review
All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + liposomal anthracycline showed no clear difference in mortality compared with HAART alone (moderate certainty).
1 finding from 1 review
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether combination Chemotherapy + ART changes mortality compared with single Agent Chemotherapy + ART (very low certainty).
1 finding from 1 review
RR 0.38 [0.24, 0.58]
50 participants
Very low
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes mortality compared with ART (very low certainty).
1 finding from 1 review
RR 0.72 [0.37, 1.43]
50 participants
Very low
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes mortality compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 0.46 [0.29, 0.73]
98 participants
Very low
All‐cause mortality · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
It is very uncertain whether d4T changes mortality compared with AZT (very low certainty).
1 finding from 1 review
Intervention not reported
Maternal mortality · Pregnant women with HIV infection
The intervention showed no clear difference in maternal mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with diarrhoea in children with HIV infection
The intervention may leads to lower mortality, all‐cause (low certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with HIV infection or exposure
The intervention showed no clear difference in mortality, all‐cause (low certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with HIV infection or exposure
The intervention probably leads to lower mortality, all‐cause (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with HIV exposure (children)
1 finding from 1 review
Intervention not reported
Mortality, all cause3 · patients with HIV infection or exposure
1 finding from 1 review
Intervention not reported
Mortality at 12 months · Children with HIV infection
The intervention showed no clear difference in mortality at 12 months (moderate certainty).
1 finding from 1 review
Mortality ‐ not measured · patients with Improving outcomes in youth living with HIV
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality ‐ not measured · patients with first‐line ART failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infant Mortality at 1 Month · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes infant Mortality at 1 Month compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Infant Mortality at 6 Months · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
1 finding from 1 review